pages:
-
A Website to Teach Children Safety with Dogs: Development and Evaluation
-
A Whole-Epigenome Approach to Identifying Novel Targets for Nano-Pharm Memory Enhancement
-
A-Z Clinical Trials Unit
-
A-Z Clinical Trials Unit
-
A20 Promotes Glioma Stem Cell Mediated Tumorigenesis
-
A5210.04-University of Alabama at Birmingham - VSL 54
-
A5272/A5280 Supplemental Funds from Adult Clinical Trials Group
-
A5280 "A Prospective, Randomized, Double-Blind Phase II Trial of High-Dose Vitamin D and Calcium for Bone Health in HIV-Infected Individuals Initiating Highly Active Antiretroviral Therapy (HAART)"
-
A5280 "A Prospective, Randomized, Double-Blind Phase II Trial of High-Dose Vitamin D and Calcium for Bone Health in HIV-Infected Individuals Initiating Highly Active Antiretroviral Therapy (HAART)"
-
A5333s: Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarker
-
A5333s:Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarker
-
A5361s: Pitavastatin to Reduce Physical Function Impairment and Frailty in HIV (PREPARE)
-
A5361s: Pitavastatin to Reduce Physical Function Impairment and Frailty in HIV (PREPARE)
-
A5361s: Pitvastatin to Reduce Physical Function Impairment and Frailty in HIV
-
A5391- Doravirine for Persons with Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)
-
AAAS Fellowship
-
AADR Proctor & Gamble Underrepresented Faculty Research Fellowship
-
AADR-Anne D. Haffajee Fellowship
-
AADVL18P1 – An Open-Label Feasibility Study to Assess the Safety and Pharmacokinetics of Enasidenib in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia R/R-AML with an Isocitrate Dehydrogenase-2 IDH2 Mutation”,
-
AAHPM Y.C. Ho/Helen & Michael Chiang Foundation 2016 Fellowship Grant
-
AALL 1521; A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2- Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Lukemia
-
AALL0434-Novartis Pharmaceuticals Corporation
-
AALL1131 Supplemental PCR
-
AALL1331 - Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467,NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
-
AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#100135, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
-
AALL1621- A Phase 2 Study of Inotuzumab Ozogamicin (NSC#772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+B-Acute Lymphoblastic Leukemia(B-ALL)
-
AALL1621- A Phase 2 Study of Inotuzumab Ozogamicin in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
-
AALL1721 - A Single Arm Phase II Trial to Assess the Efficacy and Safety of CTL019 in First Line High-Risk (HR) Pediatric and Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia (B- ALL) Who are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy
-
AALL1931 - An Open-Label, Multicenter Study of RC-P in Patients with Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to E. Coll-Derived Asparaginases
-
AAML 1031 - A Phase III Randomized Trial for Patients with De Novo AML Using Bortezomib (NSC# 681239) and Sorafenib (BAY 43-9006, NSC# 724772) for Patients with High Allelic Ratio FLT2/ITD
pages:
